Domperidone: Limited benefits with significant risk for sudden cardiac death

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 218-225

  Hondeghem, Luc M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DOMPERIDONE; PLACEBO; SULPIRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISPERSION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEART DEPOLARIZATION; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HIS BUNDLE; HUMAN; ISOLATED HEART; NAUSEA AND VOMITING; NONHUMAN; POLYMORPHIC VENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; RABBIT; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STOMACH DISEASE; STOMACH EMPTYING; STOMACH PARESIS; SUDDEN DEATH; SYSTEMATIC REVIEW; TRIANGULATION;

ACTION POTENTIALS; ANIMALS; ANTIEMETICS; DEATH, SUDDEN, CARDIAC; DOMPERIDONE; DOPAMINE ANTAGONISTS; DYSPEPSIA; ELECTROCARDIOGRAPHY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TRACT; HEART; HUMANS; MALE; OSMOLAR CONCENTRATION; PERFUSION; RABBITS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR;

EID: 84875232401     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827afd0d     Document Type: Review

References (47)

1. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036-2045.
2. Kono T, Tokumaru O, Mizumoto C, et al. Impaired gastric slow waves induced by spatial disorientation and effect of domperidone. Am J Gastroenterol. 1999;94:1224-1229.
3. Straus SM, Sturkenboom MC, Bleumink GS, et al. Non-cardiac QTcprolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007-2012.
4. De Bruin ML, Langendijk PN, Koopmans RP, et al. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2006;63:216-223.
5. Hennessy S, Leonard CE, Palumbo CM, et al. Diagnostic codes for sudden cardiac death and ventricular arrhythmia functioned poorly to identify outpatient events in EPIC's General Practice Research Database. Pharmacoepidemiol Drug Saf. 2008;17:1131-1136.
6. van Noord C, Dieleman JP, van Herpen G, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands. Drug Saf. 2010;33:1003-1014.
7. Johannes CB, Varas-Lorenzo C, McQuay LJ, et al. Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19:881-888.
8. Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic therapy with high doses domperidone and methylprednisolone. Lancet. 1984;2:1336-1337.
9. Joss RA, Goldhirsch A, Brunner WK. Sudden death in a cancer patient on high dose domperidone. Lancet. 1982;1:1019.
10. Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. Br Med J. 1984;289:1579.
11. Osborne RJ, Slevin ML, Hunter RW. Cardiotoxicity of intravenous domperidone. Lancet. 1985;2:385.
12. Bruera E, Villamyor R, Roca E. Q-T interval prolongation and ventricular fibrillation with IV domperidone. Cancer Treat Rep. 1986;70:545-546.
13. Osborne RJ, Slevin ML, Hunter RW. Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum Toxicol. 1985;4:617-623.
14. Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf. 2010;5:257-262.
15. Drolet B, Rousseau G, Daleau P, et al. Domperidone should not be considered a no-risk alternative to cisapride in the treatment of gastrointestinal motility disorders. Circulation. 2000;102:1883-8835.
16. Hondeghem LM. Low safety index of domperidone: mechanism for increased odds ratio for sudden cardiac death. Acta Cardiol. 2011;6:421-425.
17. Hondeghem LM, Lu HR, van Rossem K, et al. Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol. 2003;14:287-294.
18. Hondeghem L, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but APD prolongation is antiarrhythmic. Circulation. 2001;103:2004-2013.
19. Claassen S, Zünkler BJ. Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005;74:31-36.
20. US Food and Drug Administration. FDA Warns Against Women Using Unapproved Drug, Domperidone, to Increase Milk Production. FDA Talk PaperT04-T17; June 7, 2004. Available at: http://www.fda.gov/ Drugs/DrugSafety/InformationbyDrugClass/ ucm173886.htm. Accessed December 2012.
21. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
22. Hondeghem LM. Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur J Pharmacol. 2008;584:1-9.
23. AVMA Panel on Euthanasia. AVMA Guidelines on Euthanasia, June 2007. http://www.avma.org/issues/animal-welfare/euthanasia.pdf. Accessed December 2012.
24. Institute for Laboratory Animal Research (ILAR). Guide for the Care and Use of Laboratory Animals. http://www.nap.edu/catalog.php?record-id=12910.
25. Hondeghem LM. Computer aided development of antiarrhythmic agents with class IIIa properties. J Cardiovasc Electrophysiol. 1994;5:711-721.
26. Wonnacott TH, Wonnacott RJ. Introductory Statistics. 3rd ed. New York, NY: J Wiley & Sons; 1977.
27. Itoh H, Katagiri F, Ikawa K, et al.Effects of domperidone on human plasma levels of motilin, somatostatin, gastrin, adrenocorticotropic hormone and cortisol. Biol Pharm Bull. 2005;28:1752-1756.
28. Hondeghem LM, Dujardin K, Hoffmann P, et al. Drug-induced QTC prolongation dangerously underestimates proarrhythmic potential: lessons from terfenadine. J Cardiovasc Pharmacol. 2011;57:589- 597.
29. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol. 2005;59:725-729.
30. Tighe MP, Afzal NA, Bevan A, et al. Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review. Paediatr Drugs. 2009;11:185-202.
31. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008;6:726-733.
32. Corazzao GR, Biagi F, Albano O, et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind controlled trial. Ital J Gastroenterol. 1996;28:317-323
33. Lewis T, Drury AN. Revised views of refractory period in relation to drugs reputed to pro-long it and in relation to circus movement. Heart. 1926;13:95-100.
34. Shah RR, Hondeghem LM. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm. 2005;2:758-772.
35. Maddern GJ, Kiroff GK, Leppard PI, et al. Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol. 1986;8:135-140.
36. Sakamoto Y, Kato S, Sekino Y, et al. Effects of domperidone on gastric emptying: a crossover study using a continuous real-time 13C breath test (BreathID system). Hepatogastroenterology. 2011;58:637-641.
37. Markey O, Shafat A. Does domperidone, a D(2)-antagonist alter gastric emptying rates and appetite sensations in healthy adults with high-fat meal? A block-randomised, single-blind placebo-controlled study. Ir J Med Sci. 2012;181:215-219.
38. Prakash A, Wagstaff AJ. Domperidone. A review of its use in diabetic gastropathy. Drugs. 1998;56:429-445.
39. Takahashi T, Kurosawa S, Wiley JW, et al. Mechanism for gastrokinetic action of domperidone. In vitro studies in guinea pig. Gastroenterology. 1991;101:703-710.
40. Braun AP. Domperidone in the treatment of symptoms of delayed gastric emptying in diabetic patients. Adv Ther. 1989;6:51-62.
41. Lu HR, Marien R, Saels A, et al. Species plays an important role in druginduced prolongation of action potential duration and early after depolarizations in isolated Purkinje fibers. J Cardiovasc Electrophysiol. 2001; 12:93-102.
42. Ward BA, Alan Morocho A, Kandil A, et al. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Pharmacol. 2004;58:277-287.
43. Couture L, Nash JA, Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev. 2006;58:244-258.
44. Reiche R, Plante I, Drolet B, et al. Lengthening of cardiac repolarization in isolated guinea pigs hearts by sequential or concomitant administration of two IKr blockers. J Pharm Sci. 2011;100:2469-2481.
45. De Ponti F, Poluzzi E, Vaccheri A, et al. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br J Clin Pharmacol. 2002;54:171-177.
46. Hale T: Medications and Moother's Milk. 11th ed. Amarillo, TX: Pharmasoft Publishing; 2004:259.
47. Boyce MJ, Baisley KJ, Warrington SJ. Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study. Br J Clin Pharmacol. 2011 [Epub ahead of print].